Study of Genetic Effects on Response to Oral Semaglutide in Adults with Normal to Pre-Diabetes Using Mixed Meal Tests Before and After Treatment

What this Trial Is About

Researchers are studying how genetic differences affect the bodys response to oral semaglutide, a medication approved to treat type 2 diabetes. The study aims to understand how this drug influences blood sugar and other metabolic factors after consuming a standardized mixed meal. By comparing responses before and after treatment, the researchers hope to gain insights into drug mechanisms and the development of type 2 diabetes. Participants will undergo a mixed meal tolerance test MMTT on the first day, where blood samples are taken at multiple time points after eating a meal with set amounts of protein, carbohydrates, and fat. From days 3 to 15, participants will take 7 mg of oral semaglutide daily. On day 16, they will take their final dose and repeat the MMTT with blood draws over two hours to observe changes while on the medication. During the study visits, participants will have vital signs checked, fasting blood drawn, and anthropometric measurements taken. Blood samples will be collected at various intervals after meals to measure sugars, fats, metabolites, and proteins. The main outcomes measured include insulin response and glucose levels after 15 days of treatment. The total participation time is about 16 days, with close monitoring of physiological changes before and after oral semaglutide use.

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH